Business Context and Reporting Period
This Form 8-K Current Report is filed by Inhibikase Therapeutics, Inc. (IKT) on August 21, 2026. The filing addresses a significant corporate governance event: the change of the Company's independent registered public accounting firm.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the dismissal of the prior auditor and the appointment of a new one.
Material Changes
- Dismissal of Auditor: On August 21, 2026, the Audit Committee dismissed CohnReznick LLP as the independent registered public accounting firm, effective immediately.
- Appointment of New Auditor: On the same date, the Audit Committee appointed Deloitte & Touche LLP as the new independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Audit History: CohnReznick's audit reports for fiscal years 2024 and 2025 were unqualified and did not contain adverse opinions or disclaimers.
- Prior Material Weakness: CohnReznick previously identified a material weakness in internal controls over financial reporting in fiscal 2024. The Company disclosed this in its Q2 2024 10-Q and stated it was remediated by prior management, as disclosed in the Q3 2024 10-Q.
- No Disagreements: The Company reported no disagreements with CohnReznick regarding accounting principles, practices, or auditing scope during the relevant periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of new risks or contingencies beyond the standard disclosure regarding the change in auditors. The Company confirmed that no consultations were held with Deloitte regarding accounting principles or reportable events prior to their appointment.
Investor Verification Checklist
- Verify the reasons for the auditor change by reviewing the letter from CohnReznick LLP filed as Exhibit 16.1.
- Confirm the status of the previously disclosed material weakness in internal controls by reviewing the Q3 2024 Form 10-Q.
- Monitor future filings for the first audit report issued by Deloitte & Touche LLP.
- Check for any subsequent 8-K filings that might disclose disagreements or reportable events not mentioned in this initial report.